Dr. Sashi Adigopula, M.D
NPI: 1053325050
Total Payments
$199,338
2024 Payments
$100,935
Companies
22
Transactions
255
Medicare Patients
740
Medicare Billing
$91,944
Payment Breakdown by Category
Other$159,755 (80.1%)
Consulting$18,288 (9.2%)
Travel$13,749 (6.9%)
Food & Beverage$7,356 (3.7%)
Education$189.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $159,755 | 62 | 80.1% |
| Consulting Fee | $18,288 | 8 | 9.2% |
| Travel and Lodging | $13,749 | 18 | 6.9% |
| Food and Beverage | $7,356 | 164 | 3.7% |
| Education | $189.98 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $103,953 | 59 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $42,427 | 42 | $0 (2024) |
| Abbott Laboratories | $12,020 | 42 | $0 (2024) |
| Lilly USA, LLC | $8,564 | 6 | $0 (2024) |
| United Therapeutics Corporation | $8,480 | 12 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $7,998 | 31 | $0 (2024) |
| SCPHARMACEUTICALS INC. | $7,850 | 5 | $0 (2024) |
| CVRx, Inc. | $6,580 | 17 | $0 (2024) |
| Boston Scientific Corporation | $327.32 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $192.03 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $100,935 | 93 | Boehringer Ingelheim Pharmaceuticals, Inc. ($55,443) |
| 2023 | $68,272 | 58 | Boehringer Ingelheim Pharmaceuticals, Inc. ($48,488) |
| 2022 | $7,592 | 24 | AstraZeneca Pharmaceuticals LP ($7,143) |
| 2021 | $7,909 | 10 | AstraZeneca Pharmaceuticals LP ($7,850) |
| 2020 | $6,707 | 7 | Abbott Laboratories ($6,588) |
| 2019 | $372.10 | 14 | SANOFI-AVENTIS U.S. LLC ($108.80) |
| 2018 | $7,078 | 39 | CVRx, Inc. ($6,422) |
| 2017 | $472.27 | 10 | Abbott Laboratories ($217.99) |
All Payment Transactions
255 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: DIABETES | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Consulting Fee | Cash or cash equivalent | $2,725.00 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | Cash or cash equivalent | $174.36 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: Heart Failure | ||||||
| 12/05/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $39.44 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | Cash or cash equivalent | $32.69 | General |
| Category: Cardiology | ||||||
| 12/04/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | Cash or cash equivalent | $25.49 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | In-kind items and services | $1,026.28 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | In-kind items and services | $324.90 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| Category: Cardiology | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: DIABETES | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: DIABETES | ||||||
| 11/18/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2024 | United Therapeutics Corporation | — | Food and Beverage | Cash or cash equivalent | $116.71 | General |
| 10/31/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $102.99 | General |
| Category: DIABETES | ||||||
| 10/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Consulting Fee | Cash or cash equivalent | $2,725.00 | General |
| Category: Cardiology | ||||||
| 09/06/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $8.25 | General |
| Category: Cardiology | ||||||
| 08/21/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $2,194.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 195 | 330 | $70,223 | $26,529 |
| 2022 | 7 | 216 | 309 | $62,510 | $23,143 |
| 2021 | 7 | 214 | 357 | $66,410 | $27,124 |
| 2020 | 5 | 115 | 203 | $30,920 | $15,147 |
Total Patients
740
Total Services
1,199
Medicare Billing
$91,944
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 153 | $42,880 | $13,585 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 75 | $13,385 | $6,841 | 51.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 44 | $5,816 | $2,782 | 47.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $3,984 | $1,763 | 44.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $2,288 | $1,065 | 46.5% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 14 | 15 | $1,230 | $331.90 | 27.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 16 | 16 | $640.00 | $161.53 | 25.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 106 | $31,800 | $8,157 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 61 | 68 | $11,084 | $6,322 | 57.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 45 | $5,085 | $2,451 | 48.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $5,229 | $2,200 | 42.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $3,991 | $1,930 | 48.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 27 | $2,943 | $1,448 | 49.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 28 | 29 | $2,378 | $635.70 | 26.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 48 | 163 | $39,528 | $12,404 | 31.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 79 | 94 | $15,322 | $8,975 | 58.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 18 | 19 | $3,952 | $1,982 | 50.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 29 | $3,161 | $1,822 | 57.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 27 | $2,943 | $1,492 | 50.7% |
| 94618 | Test for exercise-induced lung stress | Office | 2021 | 12 | 12 | $984.00 | $308.76 | 31.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 12 | 13 | $520.00 | $141.89 | 27.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 32 | 108 | $17,064 | $8,566 | 50.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 37 | 41 | $6,683 | $2,905 | 43.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 26 | $2,834 | $1,450 | 51.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $2,704 | $1,374 | 50.8% |
About Dr. Sashi Adigopula, M.D
Dr. Sashi Adigopula, M.D is a Advanced Heart Failure and Transplant Cardiology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053325050.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sashi Adigopula, M.D has received a total of $199,338 in payments from pharmaceutical and medical device companies, with $100,935 received in 2024. These payments were reported across 255 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($159,755).
As a Medicare-enrolled provider, Adigopula has provided services to 740 Medicare beneficiaries, totaling 1,199 services with total Medicare billing of $91,944. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Advanced Heart Failure and Transplant Cardiology
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location Indianapolis, IN
- Active Since 07/28/2006
- Last Updated 01/16/2026
- Taxonomy Code 207RA0001X
- Entity Type Individual
- NPI Number 1053325050
Products in Payments
- JARDIANCE (Drug) $112,517
- FARXIGA (Drug) $34,191
- LOKELMA (Drug) $8,006
- FUROSCIX (Drug) $7,850
- OPSUMIT (Drug) $7,388
- Barostim Neo System (Device) $6,580
- MITRACLIP (Device) $4,256
- CardioMEMS HF System (Device) $3,778
- HeartMate 3 Left Ventricular Dev (Device) $3,245
- TYVASO (Drug) $2,044
- UPTRAVI (Drug) $556.57
- CARDIOMEMS (Device) $366.98
- Circulatory Support (Device) $253.82
- WATCHMAN FLX (Device) $168.39
- ENTRESTO (Drug) $167.09
- HeartWare HVAD (Device) $136.68
- CAMZYOS (Drug) $130.00
- WATCHMAN Access System (Device) $122.84
- WAINUA (Drug) $121.18
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $120.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Advanced Heart Failure and Transplant Cardiology Doctors in Indianapolis
Dr. David Kovacich, M.d, M.D
Advanced Heart Failure and Transplant Cardiology — Payments: $666,196
Advanced Heart Failure and Transplant Cardiology $666,196
Rafael Garcia-Cortes, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $82,921
Advanced Heart Failure and Transplant Cardiology $82,921
Radha Kanneganti Perue, Mbbs, MBBS
Advanced Heart Failure and Transplant Cardiology — Payments: $12,622
Advanced Heart Failure and Transplant Cardiology $12,622
Angela Brittsan, M.d, M.D
Advanced Heart Failure and Transplant Cardiology — Payments: $8,661
Advanced Heart Failure and Transplant Cardiology $8,661
Joanna Pasley, Agnp-C, AGNP-C
Advanced Heart Failure and Transplant Cardiology — Payments: $465.37
Advanced Heart Failure and Transplant Cardiology $465.37
Polly Moore, Md, MD
Advanced Heart Failure and Transplant Cardiology — Payments: $231.39
Advanced Heart Failure and Transplant Cardiology $231.39